Do We Get Samples of the Report?

Yes, you will receive a sample copy of the market research report from the sales team when you put a query to us. The sample report is free and offers a brief view of the report and information on data available before you purchase the full-fledged report. Also, we will provide a demo sample for any oncoming study.

How to Buy a Market Report?

Select the report you wish to purchase and proceed to buy it by making an online payment. We use a secured gateway for payment transfers and do not share your financial information with any unconcerned third party.

In Which Format Will I Get the Report?

The report will be delivered in spreadsheet and PDF format. In some cases, PPT formats could be available as well.

In How Much Time I will Get the Report After Purchase?

After confirmation of the payment, you will receive the electronic format of the report at your registered email address in (mention the timeline for the delivery). If you buy a report over a holiday or weekend, we will process the request the next working day.

How Can I Get the Report Customized?

Market studies and reports already contain important data and are ready for distribution to the purchaser. However, if there is any particular query, addition, or customization you require, then contact us on our email id or phone. We will look to accommodate your request and see what can be done at the earliest. The research team will design the report accordingly and discuss the solutions beforehand with you.

How Much Will It Cost to Get a Report Customized?

The price of the customized report will be conveyed to you by our team after we agree on the deliverable. A delivery timeline will be set so that you get the report within the expected date. Any requests for customizations after selling the report will be handled by a separate department and the prices for the same mentioned upfront.

Can I Buy Only a Particular Segment of the Study?

While usually such a request is not accommodated as any market research report is wholesome and the cost of the report is for overall contents, in special cases, we may be able to sell select segments of the report based on your requirements.

Is There Any Available Discount?

Our team will love to support academicians, start-ups, students, and others with consulting and research. Thus, our pricing plan is based on keeping these interests in mind and is already affordable. However, we may have discounts available for particular customer types and reports. So, contact us for more information.

Which Services Are Complimentary Before Purchasing the Report?

We have consumer-centric reports and offer several facilities before selling. You will get a free review and sample report, talk to our customer care team for any additions to be done and meet special requirements, and interact with our analysts for deeper understanding.

Will I Receive a Bill or Invoice for the Report Purchased?

Yes, you will get an invoice for the purchase you made. The invoice will be sent to you electronically on your registered email id.

What If I am Unable to Find the Report in the Catalog?

We have a vast database of market reports and studies and there are a few which may not have been uploaded yet. If you are unable to find the one you want, then get in touch with our sales team by phone or email and we will connect with you for assistance.

How Often Are the Existing Studies Updated?

Not every study is the same. Thus, the update for reports will depend on the ongoing research and changes if any to be incorporated in the document or not.

What If the Report Does Not Contain the Information I Want?

The market research reports are constructed keeping in mind the industry trends, nature of the study, and required inputs. But if you want something more than what is stated in the report, we can help you out with further research if possible. Contact us right away, and we will do the needful to aid you.

Is the Payment Refundable?

Once the payment is done, it is non-refundable because as per the standard policy, the utility of the reports is based on knowledge sharing, and thus, a refund is not possible to make after we have issued you obtain the study. To avoid the hassle, we have a detailed view of the report and its ideas through a sample report.

What If the Payment Fails?

If the payment fails then be assured that you shall receive the money back to the source payment mode from the payment gateway. Aarkstore is not responsible for any loss of payment in the process.

Can I Avail the Report of a Particular Country/Region?

Yes, we can provide a report or segment related to a particular region or geography if we have that feature available for the document.

Do You Offer Support After Purchase?

Yes, we are here to solve any queries you may have for the report from our analyst till a given timeframe. To understand more about this, get in touch with us.

Treatment-Resistant Depression (TRD)�market-2028

DESCRIPTION

TABLE OF CONTENTS

RELATED REPORTS

SAMPLE REQUEST

REVIEWS

DESCRIPTION

Treatment-Resistant Depression (TRD)market-2028 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology as well as the market trends of Treatment-Resistant Depression in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan. The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, the current and forecasted market size of Treatment-Resistant Depression from 2017 to 2028 segmented by seven major markets.
The phenomenon of Treatment-resistant depression (TRD) is described as the occurrence of an inadequate response after adequate treatment with antidepressant agents (in terms of dose, duration, and adherence). It has been broadly defined in the context of major depression disorder (MDD) (unipolar major depression), but alternative definitions for bipolar depression have also been suggested.
The European Unions Committee for Human Proprietary Medicinal Products (CHMP) defines TRD as follows: A patient is considered therapy-resistant (TRD) when consecutive treatments with two different antidepressant products, used for a sufficient length of time at an adequate dose with adequate affirmation of treatment adherence, fail to induce a clinically meaningful improvement.
Geography Covered
The United States
EU5 (Germany, France, Italy, Spain, and the United Kingdom)
Japan
Study Period: 20172028
Treatment-Resistant Depression - Disease Understanding and Treatment Algorithm
The classification of TRD in stages has been recently proposed where increasing resistance is equated with an increased failure to respond to antidepressant strategies. The rationale behind this approach is the clinical impression that the greater the degree of treatment resistance, the lower the probability of response to any new treatment. This perspective has yet to be empirically tested, and it is important to keep in mind that all classifications of TRD are not diagnoses per se.
A relatively wide variety of treatment options for unipolar TRD are available, whilst the evidence is very scanty for bipolar TRD. TRD is associated with poor clinical, functional, and social outcomes. Several novel therapeutic options are currently being investigated as promising alternatives, targeting the neurotransmitter system outside of the standard monoamine hypothesis.
Treatment-Resistant Depression Epidemiology
The Treatment-Resistant Depression epidemiology division provides insights about historical and current patient pool and forecasted trends for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders (KOL).
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (Total Diagnosed Prevalent cases, Gender-Specific Prevalence, and Age-Specific Prevalence) scenario of Treatment-Resistant Depression in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2017 to 2028.
According to DelveInsight, the total prevalent cases of Treatment-Resistant Depression (TRD) in the 7MM was found to be 8,339,329 in 2017. The prevalence of Treatment-Resistant Depression in the 7MM is expected to increase during the study period of 20172028.
Treatment-Resistant Depression Drug Chapters
This segment of the Treatment-Resistant Depression report encloses the detailed analysis of marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.
At present, the therapeutic market size of TRD in the US is mainly accounted for the management options consisting of pharmacologic treatment options and non-pharmacological therapies.
Pharmacologic treatment options include switching, combination and potentiation strategy among the commonly used antidepressant drugs. Most of the available antidepressants, such as Selective Serotonin Reuptake Inhibitor (SSRI), Dual serotonin and norepinephrine reuptake inhibitors (SNRIs), Tricyclic antidepressant, Irreversible, non-selective monoamine oxidase inhibitors (MAOIs), ?2-antagonists, Agomelatine, Tianeptine are used to treat TRD.
Spravato and Symbyax are the two FDA approved drugs specifically for the treatment of TRD. Other pharmacologic alternatives are also considered for those having an antidepressant action, such as in monotherapy: Bupropion, selective and reversible MAOIs, Quetiapine and in combination with a first-line antidepressant: Lithium, Lamotrigine and second-generation antipsychotics.
Non-pharmacological therapies include electroconvulsive therapy (ECT), Repetitive transcranial magnetic stimulation (rTMS), and Vagus nerve stimulation (VNS). Along with this, two alternative forms of psychotherapy involve majorly cognitive-behavioral therapy (CBT) and interpersonal therapy (IPT).
Detailed chapters of current therapies, such as Symbyax (olanzapine and fluoxetine hydrochloride) (Eli Lilly and Company), Spravato (Esketamine) (Johnson & Johnson), and emerging therapies, such as ALKS 5461 (Alkermes), AXS-05 (Axsome Therapeutics), Cariprazine (Allergan/Gedeon Richters), Pimavanserin (Acadia Pharmaceuticals), Seltorexant (J&J/ Minerva Neurosciences), Esketamine DPI (Celon Pharma), REL-1017 (Relmada Therapeutics), AV-101 (Vistagen therapeutics), and others have also been provided in the report.
Treatment-Resistant Depression Market Outlook
The Treatment-Resistant Depression market outlook of the report helps to build a detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.
According to DelveInsight, the market for Treatment-Resistant Depression in 7MM was found to be approximately USD 3,698.34 Million in 2017.
Treatment-Resistant Depression market size in the United States accounted for 71% of the total market in 2017. The US led the market in 2017, followed by the EU5 and Japan, respectively. Due to the high prevalence of this disease in the region, the Treatment-Resistant Depression treatment market in the US is expected to dominate the market during the forecast period (20192028).
Treatment-Resistant Depression Drugs Uptake
This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2017 to 2028. The analysis covers market uptake by drugs; patient uptake by therapies, and sales of each drug.
The dynamics of Treatment-Resistant Depression market is anticipated to change in the coming years owing to the expected launch of emerging therapies, such as, AXS-05 (Axsome Therapeutics), ALKS-5461 (Alkermes), Esketamine Nasal Spray (Janssen Pharmaceuticals), Cariprazine (Allergan/ Gedeon Richter), Seltorexant (Minerva Neurosciences), Rapastinel (Naurex), Seltorexant (Minerva Neurosciences), Pimavanserin (Acadia Pharmaceuticals), and AV-101 (VistaGen Therapeutics), and others in the Treatment-Resistant Depression market by 2028.
Treatment-Resistant Depression Report Insights
Patient Population of Treatment-Resistant Depression
Therapeutic Approaches
Pipeline Analysis
Market Size and Trends
Market Opportunities
Impact of upcoming Therapies
Treatment-Resistant Depression Report Key Strengths
10-Year Forecast
7MM Coverage
Epidemiology Segmentation
Drugs Uptake
Highly Analyzed Market
Key Cross Competition
Treatment-Resistant Depression Report Assessment
Current Treatment Practices
Unmet Needs
Detailed Pipeline Product Profiles
Market Attractiveness
Market Drivers and Barriers
Key Benefits
This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving Treatment-Resistant Depression market
Organize sales and marketing efforts by identifying the best opportunities for Treatment-Resistant Depression market
To understand the future market competition in the Treatment-Resistant Depression market

TABLE OF CONTENTS

List Of Tables

Table 1: Thase and Rush Staging Method
Table 2: Thase and Rush Staging Method
Table 3: The European Staging Method
Table 4: Massachusetts General Hospital Staging Method
Table 5: Major Depressive Disorder Diagnostic Criteria according to DSM-IV-TR
Table 6: Depressive Episode Criteria (maybe part of Major Depressive Disorder OR an isolated episode)
Table 7: DSM-IV-TR diagnostic criteria - MDD
Table 8: DSM-IV-TR diagnostic criteria for MDD, Single episode
Table 9: DSM-IV-TR diagnostic criteria for MDD, Recurrent
Table 10: Selected DSM-IV-TR Major Depressive Episode Specifier
Table 11: Major depressive disorder diagnostic criteria according to DSM-V
Table 12: Severity/course specifier
Table 13: Prevalent Patient Population of Treatment-Resistant Depression in 7MM (20172028)
Table 14: Total Diagnosed Prevalent Cases of Treatment-Resistant Depression in the United States (20172028)
Table 15: Gender-Specific Cases of Treatment-Resistant Depression in the United States (20172028)
Table 16: Age-Specific Cases of Treatment-Resistant Depression in the United States (20172028)
Table 17: Total Diagnosed Prevalent Cases of Treatment-Resistant Depression in Germany (20172028)
Table 18: Gender-Specific Cases of Treatment-Resistant Depression in Germany (20172028)
Table 19: Age-Specific Cases of Treatment-Resistant Depression in Germany (20172028)
Table 20: Total Diagnosed Prevalent Cases of Treatment-Resistant Depression in France (20172028)
Table 21: Gender-Specific Cases of Treatment-Resistant Depression in France (20172028)
Table 22: Age-Specific Cases of Treatment-Resistant Depression in France (20172028)
Table 23: Total Diagnosed Prevalent Cases of Treatment-Resistant Depression in Italy (20172028)
Table 24: Gender-Specific Cases of Treatment-Resistant Depression in Italy (20172028)
Table 25: Age-Specific Cases of Treatment-Resistant Depression in Italy (20172028)
Table 26: Total Diagnosed Prevalent Cases of Treatment-Resistant Depression in Spain (20172028)
Table 27: Gender-Specific Cases of Treatment-Resistant Depression in Spain (20172028)
Table 28: Age-Specific Cases of Treatment-Resistant Depression in Spain (20172028)
Table 29: Total Diagnosed Prevalent Cases of Treatment-Resistant Depression in the United Kingdom (20172028)
Table 30: Gender-Specific Cases of Treatment-Resistant Depression in the United Kingdom (20172028)
Table 31: Age-Specific Cases of Treatment-Resistant Depression in the United Kingdom (20172028)
Table 32: Total Diagnosed Prevalent Cases of Treatment-Resistant Depression in Japan (20172028)
Table 33: Gender-Specific Cases of Treatment-Resistant Depression in Japan (20172028)
Table 34: Age-Specific Cases of Treatment-Resistant Depression in Japan (20172028)
Table 35: Limited response and Treatment-Resistant depression
Table 36: Recommendations for treatment potentiation
Table 37: Esketamine Nasal Spray, Clinical Trial Description, 2019
Table 38: Emerging Drugs Analysis Key potential therapies
Table 39: Emerging Drugs Analysis Other potential therapies
Table 40: Emerging Drugs Analysis Other potential therapies
Table 41: ALKS 5461, Clinical Trial Description, 2018
Table 42: AXS-05, Clinical Trial Description, 2019
Table 43: Cariprazine, Clinical Trial Description, 2019
Table 44 Pimavanserin, Clinical Trial Description, 2019
Table 45: Seltorexant, Clinical Trial Description, 2019
Table 46: Esketamine DPI, Clinical Trial Description, 2019
Table 47: REL-1017, Clinical Trial Description, 2019
Table 48: AV-101, Clinical Trial Description, 2019
Table 49: Rapastinel, Clinical Trial Description, 2019
Table 50: MIN-117, Clinical Trial Description, 2019
Table 51: Clinical Trial Description, 2019
Table 52: Psilobycin, Clinical Trial Description, 2019
Table 53: 7 Major Market Size of Treatment-Resistant Depression in USD Million (20172028)
Table 54: United States Market Size of TRD in USD Million (20172028)
Table 55: Market Size of TRD by Current Therapies in USD Million (20172028)
Table 56: US TRD Market size by Emerging Therapies in USD Million (20172028)
Table 57: Germany Market Size of TRD in USD Million (20172028)
Table 58: Market Size of TRD by Current Therapies in USD Million (20172028)
Table 59: Germany TRD Market size by Emerging Therapies in USD Million (20172028)
Table 60: France Market Size of TRD in USD Million (20172028)
Table 61: Market Size of TRD by Current Therapies in USD Million (20172028)
Table 62: France TRD Market size by Emerging Therapies in USD Million (20172028)
Table 63: Italy Market Size of TRD in USD Million (20172028)
Table 64: Market Size of TRD by Current Therapies in USD Million (20172028)
Table 65: Italy TRD Market size by Emerging Therapies in USD Million (20172028)
Table 66: Spain Market Size of TRD in USD Million (20172028)
Table 67: Market Size of TRD by Current Therapies in USD Million (20172028)
Table 68: Spain TRD Market size by Emerging Therapies in USD Million (20172028)
Table 69: United Kingdom Market Size of TRD in USD Million (20172028)
Table 70: Market Size of TRD by Current Therapies in USD Million (20172028)
Table 71: UK TRD Market size by Emerging Therapies in USD Million (20172028)
Table 72: Japan Market Size of TRD in USD Million (20172028)
Table 73: Market Size of TRD by Current Therapies in USD Million (20172028)
Table 74: Japan TRD Market size by Emerging Therapies in USD Million (20172028)

List Of Figures

Figure 1: Signs and Symptoms of Treatment-Resistant Depression
Figure 2: Differential Diagnosis
Figure 3: Total Diagnosed Prevalent Patient Population of TRD in 7MM (20172028)
Figure 4: Total Diagnosed Prevalent Cases of Treatment-Resistant Depression in the US (20172028)
Figure 5: Gender-Specific Cases of Treatment-Resistant Depression in the United States (20172028)
Figure 6: Age-Specific Cases of Treatment-Resistant Depression in the United States (20172028)
Figure 7: Total Diagnosed Prevalent Cases of TRD in Germany (20172028)
Figure 8: Gender-Specific Cases of Treatment-Resistant Depression in Germany (20172028)
Figure 9: Age-Specific Cases of Treatment-Resistant Depression in Germany (20172028)
Figure 10: Total Diagnosed Prevalent Cases of TRD in France (20172028)
Figure 11: Gender-Specific Cases of Treatment-Resistant Depression in France (20172028)
Figure 12: Age-Specific Cases of Treatment-Resistant Depression in France (20172028)
Figure 13: Total Diagnosed Prevalent Cases of Treatment-Resistant Depression in Italy (20172028)
Figure 14: Gender-Specific Cases of Treatment-Resistant Depression in Italy (20172028)
Figure 15: Age-Specific Cases of Treatment-Resistant Depression in Italy (20172028)
Figure 16: Total Diagnosed Prevalent Cases of Treatment-Resistant Depression in Spain (20172028)
Figure 17: Gender-Specific Cases of Treatment-Resistant Depression in Spain (20172028)
Figure 18: Age-Specific Cases of Treatment-Resistant Depression in Spain (20172028)
Figure 19: Total Diagnosed Prevalent Cases of TRD in the UK (20172028)
Figure 20: Gender-Specific Cases of TRD in the United Kingdom (20172028)
Figure 21: Age-Specific Cases of Treatment-Resistant Depression in the United Kingdom (20172028)
Figure 22: Total Diagnosed Prevalent Cases of Treatment-Resistant Depression in Japan (20172028)
Figure 23: Gender-Specific Cases of Treatment-Resistant Depression in Japan (20172028)
Figure 24: Age-Specific Cases of Treatment-Resistant Depression in Japan (20172028)
Figure 25: Recommendations for Switching ADT
Figure 26: Unmet Needs
Figure 27: 7 Major Market Size of Treatment-Resistant Depression in USD Million (20172028)
Figure 28: Market Size of TRD in the US, USD Millions (20172028)
Figure 29: Market Size of TRD by Current Therapies in USD Million (20172028)
Figure 30: Market Size of TRD by Emerging Therapies in USD Million (20172028)
Figure 31: Market Size of TRD in Germany, USD Millions (20172028)
Figure 32: Market Size of TRD by Current Therapies in USD Million (20172028)
Figure 33: Market Size of TRD by Emerging Therapies in USD Million (20172028)
Figure 34: Market Size of TRD in France USD Millions (20172028)
Figure 35: Market Size of TRD by Current Therapies in USD Million (20172028)
Figure 36: Market Size of TRD by Emerging Therapies in USD Million (20172028)
Figure 37: Market Size of Treatment-Resistant Depression (TRD) in Italy, USD Millions (20172028)
Figure 38: Market Size of TRD by Current Therapies in USD Million (20172028)
Figure 39: Market Size of TRD by Emerging Therapies in USD Million (20172028)
Figure 40: Market Size of TRD in Spain, USD Millions (20172028)
Figure 41: Market Size of TRD by Current Therapies in USD Million (20172028)
Figure 42: Market Size of TRD by Emerging Therapies in USD Million (20172028)
Figure 43: Market Size of TRD in the United Kingdom, USD Millions (20172028)
Figure 44: Market Size of TRD by Current Therapies in USD Million (20172028)
Figure 45: Market Size of TRD by Emerging Therapies in USD Million (20172028)
Figure 46: Market Size of Treatment-Resistant Depression in Japan, USD Millions (20172028)
Figure 47: Market Size of TRD by Current Therapies in USD Million (20172028)
Figure 48: Market Size of TRD by Emerging Therapies in USD Million (20172028)
Figure 49: Market Drivers
Figure 50: Market Barriers

RELATED REPORTS

Fill The Form For Sample Request

Full Name*

Business Email *

E-mail

Country *

Contact No *

Alternate No

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

REVIEWS

There is no Reviews available

Search and Get the Latest Market Research Reports

Treatment-Resistant Depression (TRD)�market-2028

Leading Pharmaceutical Contract Development Manufacturing Organizations

Wuxi Biologics Performance Capabilities Goals Strategies

U.S Infectious Disease Testing Market Shares

U.S Infectious Disease Testing Market Shares

FAQs